Amarin Corp issued the following announcement on April 12.
These analyses highlight the need for further research in patients with reduced kidney function in conjunction with diabetes mellitus or ongoing inflammation, as denoted by elevated high sensitivity C-reactive protein (hsCRP) levels, and persistent high triglycerides (TG) despite statin therapy due to the association with increased cardiovascular disease (CVD) risk.
The poster titled "Icosapent Ethyl Reduces Potentially Atherogenic Lipid and Inflammatory Markers in High-Risk Statin-Treated Patients With Persistent High Triglycerides, eGFR < 90 mL/min/1.73 m2, and Diabetes Mellitus" showed that, consistent with overall ANCHOR study results, compared with placebo, icosapent ethyl (IPE) 4g/day significantly decreased the primary endpoint of triglycerides (TG) (−19.7%; P < 0.0001) and other lipids without increasing LDL-C. Apolipoproteins and markers of oxidation and inflammation were significantly improved.
This poster was authored by: Harold M. Szerlip, MD, Baylor University Medical Center Dallas, TX; Krishnaswami Vijayaraghavan, MD, Abrazo Arizona Heart Hospital, Phoenix, AZ; Christie M. Ballantyne, MD, Baylor College of Medicineand the Houston Methodist DeBakey Heart and Vascular Center, Houston, TX; Harold E. Bays, MD, Louisville Metabolic and Atherosclerosis Research Center, Louisville, KY; Craig Granowitz, MD, PhD, Ralph T Doyle, Rebecca A. Juliano, PhD, & Sephy Philip, RPh, PharmD, Amarin Pharma, Inc., Bedminster, NJ.
The poster titled "Icosapent Ethyl Reduces Potentially Atherogenic Lipid and Inflammatory Markers in High-Risk Statin-Treated Patients With Persistent High Triglycerides, eGFR < 90 mL/min/1.73 m2, and Elevated High-Sensitivity C-Reactive Protein ≥2.0 mg/L" showed that, consistent with overall ANCHOR study results, in statin-treated patients with reduced kidney function and elevated high-sensitivity C-reactive protein (hsCRP) with persistent high TG, IPE 4g/day reduced TG and other potentially atherogenic and inflammatory markers without raising low-density cholesterol vs. placebo. This poster was authored by: Krishnaswami Vijayaraghavan, MD, Abrazo Arizona Heart Hospital, Phoenix, AZ; Harold M. Szerlip, MD, Baylor University Medical Center Dallas, TX; Christie M. Ballantyne, MD, Baylor College of Medicine and the Houston Methodist DeBakey Heart and Vascular Center, Houston, TX; John R. Nelson, MD, California Cardiovascular Institute, Fresno, CA; Craig Granowitz, MD, PhD, Ralph T Doyle, Rebecca A. Juliano, PhD, & Sephy Philip, RPh, PharmD, Amarin Pharma, Inc., Bedminster, NJ.
Both posters reported data from post hoc analyses in statin-treated patients with reduced kidney function and diabetes or elevated hsCRP with persistent high (200-499 mg/dL) TG. In these patients, prescription pure EPA Vascepa® at 4g/day, compared to placebo, showed reductions in TG and other potentially atherogenic lipid and inflammatory markers.
"More research is needed in elucidating future CV risk in patients with reduced kidney function and high triglycerides despite statin therapy," said Harold M. Szerlip, MD. "The REDUCE-IT trial will enroll some patients with characteristics presented in these posters to determine if intervention with high dose, prescription pure EPA will reduce CV events in statin-treated patients with persistent hypertriglyceridemia. I look forward to learning the results of this important study."
Original source: http://investor.amarincorp.com/releasedetail.cfm?ReleaseID=1063583
Alerts Sign-up